ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL)

1.96
-0.04
(-2.00%)
Closed October 14 4:00PM
1.96
0.00
( 0.00% )
Pre Market: 4:51AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.96
Bid
0.937
Ask
1.95
Volume
55
0.00 Day's Range 0.00
1.5735 52 Week Range 8.1939
Market Cap
Previous Close
1.96
Open
-
Last Trade
50
@
1.95
Last Trade Time
04:50:33
Financial Volume
-
VWAP
-
Average Volume (3m)
160,859
Shares Outstanding
43,702,147
Dividend Yield
-
PE Ratio
-2.29
Earnings Per Share (EPS)
-0.86
Revenue
19.94M
Net Profit
-37.37M

About Werewolf Therapeutics Inc

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Werewolf Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HOWL. The last closing price for Werewolf Therapeutics was $1.96. Over the last year, Werewolf Therapeutics shares have traded in a share price range of $ 1.5735 to $ 8.1939.

Werewolf Therapeutics currently has 43,702,147 shares outstanding. The market capitalization of Werewolf Therapeutics is $85.66 million. Werewolf Therapeutics has a price to earnings ratio (PE ratio) of -2.29.

HOWL Latest News

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of clinical activity at tolerable...

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its OngoingΒ Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical...

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

-Β  WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - -Β  Encouraging single agent clinical...

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the β€œCompany” or β€œWerewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.5076142131981.972.061.81933421.90329857CS
4-0.2-9.259259259262.162.4521.811381802.05600973CS
12-0.77-28.20512820512.732.981.661608592.16489153CS
26-2.81-58.90985324954.776.891.662411863.06334487CS
52-0.33-14.41048034932.298.19391.57354240773.45673094CS
156-15.03-88.463802236616.9917.951.392381804.09892781CS
260-16.25-89.236683141118.2123.991.392225754.93541714CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DBGIDigital Brands Group Inc
$ 0.3602
(125.41%)
5.03M
BNZIBanzai International Inc
$ 5.96
(61.08%)
126.99k
GRTSGritstone bio Inc
$ 0.073
(35.19%)
22.76M
ZPTAZapata Computing Holdings Inc
$ 0.0977
(26.88%)
10.42M
RANIRani Therapeutics Holdings Inc
$ 3.77
(18.55%)
1.26M
LGHLWLion Group Holding Ltd
$ 0.004
(-50.62%)
5.09k
QRTEBQurate Retail Inc
$ 2.14
(-44.13%)
155
STIMNeuronetics Inc
$ 0.713
(-19.89%)
1
DSYBig Tree Cloud Holdings Limited
$ 4.20
(-17.16%)
7.33k
LSBLakeShore Biopharma Company Ltd
$ 3.24
(-14.51%)
1
GRTSGritstone bio Inc
$ 0.073
(35.19%)
22.76M
ZPTAZapata Computing Holdings Inc
$ 0.0977
(26.88%)
10.43M
DBGIDigital Brands Group Inc
$ 0.3602
(125.41%)
5.03M
DJTTrump Media and Technology Group Corporation
$ 33.44
(11.65%)
1.42M
RANIRani Therapeutics Holdings Inc
$ 3.77
(18.55%)
1.26M

HOWL Discussion

View Posts
Monksdream Monksdream 1 month ago
HOWL under $3
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
HOWL under $3
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
HOWL under $10
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
HOWL new 52 week high
πŸ‘οΈ0
Pt3 Pt3 11 months ago
Yea your gap and trapped make me buy caud instead of this
πŸ‘οΈ0
TheFinalCD TheFinalCD 11 months ago
HOWL todays algo patented Gap & Trap on Phase #1 news
πŸ‘οΈ0
TheFinalCD TheFinalCD 11 months ago
Werewolf Therapeutics soars 52% premarket after presentsing preliminary monotherapy data from Phase 1/1b clinical trial establishing proof of mechanism for WTX-124$HOWL#AInvest #Ainvest_Wire #trade #source #wallstreet
View more: https://t.co/aTzfU7GqUS pic.twitter.com/rClSWzl2IS— AInvest Wire (@Ainvest_Wire) November 3, 2023
πŸ‘οΈ0
TheFinalCD TheFinalCD 11 months ago
$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL
πŸ‘οΈ0
tw0122 tw0122 12 months ago
$3 + otw Halloween is here give it a HOWL
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
dip
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
dip
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
watching
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
soon
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
insert dd
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
can be big
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
wow
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
wow
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
hold
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
slow
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
slow
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
agreed
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
like thiks
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
off radar
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
catchy name
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
catchy name
πŸ‘οΈ0
surf1944 surf1944 1 year ago
https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion
πŸ‘οΈ0
Mr. Zen Mr. Zen 2 years ago
Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

β€œThese promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. β€œThis morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL
πŸ‘οΈ0
Makk1 Makk1 2 years ago
Good call here, looking very good
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL
πŸ‘οΈ0
bobbo5 bobbo5 2 years ago
I agree and it looks like share price has been moving up this past week
πŸ‘οΈ0
dia76ca dia76ca 2 years ago
Very interesting company. I like it's chances.
πŸ‘οΈ0